Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.62 |
| ▸ | ABL1 | P00519 | 11/20 | 0.61 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29675082 | 1.00 | KIT (0.62) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL29674927 | 0.96 | KIT (0.60) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL24626613 | 0.96 | KIT (0.60) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL24626019 | 0.94 | KIT (0.66) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL29675173 | 0.94 | KIT (0.66) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL24626766 | 0.93 | KIT (0.62) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL29674993 | 0.93 | KIT (0.62) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL24626341 | 0.89 | KIT (0.79) | KITABL1FLT3FGFR1CYP2C9 | |
| SCHEMBL19322509 | 0.89 | KIT (0.79) | KITABL1FLT3SRCFGFR1 | |
| SCHEMBL24626254 | 0.89 | KIT (0.72) | KITABL1FLT3FGFR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022149855-A1 | HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-14 | — | — | WO | disclosed |